Third patient implanted with Ventracor device
Thursday, 23 October, 2003
Ventracor (ASX: VCR) has implanted its "artificial heart" device into a third patient as part of the pilot trial being conducted at the Alfred Hospital in Melbourne.
According to the chief medical investigator Prof Don Esmore, the patient is in a critical but stable condition.
He said the patient was gravely ill at the time of the procedure, and the implant was the only option available.
The announcement comes a couple of weeks after the second patient to receive the implant was discharged from hospital. The company plans to test up to ten patients in the pilot trial, before embarking on a larger, international trial.
Ventracor's share price rose four per cent yesterday after the announcement was made to close at AUD$2.49.
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
